Related Experiment Video

Updated: Jul 17, 2026

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

Alternate molecular genetic pathways in ovarian carcinomas of common histological types

Julia Willner1, Kaitlyn Wurz, Kimberly H Allison

  • 1Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Washington, Seattle, WA 98195, USA.

Human Pathology
|January 30, 2007
PubMed

Insights

This study reveals distinct molecular pathway alterations in ovarian cancer subtypes. Endometrioid and clear cell ovarian cancers show better survival and different gene mutations compared to serous types.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Epithelial ovarian tumors comprise various histological subtypes with distinct molecular characteristics.
  • Understanding these molecular differences is crucial for targeted therapies and improved patient outcomes.

Purpose of the Study:

  • To investigate and compare the mutational profiles of key genes (p53, PIK3CA, PTEN, CTNNB1, MLH1, BRAF) across common epithelial ovarian tumor subtypes.
  • To identify distinct molecular pathway alterations associated with different histological subsets of ovarian cancer.
  • To correlate these molecular alterations with tumor grade, stage, and patient survival.

Main Methods:

  • Direct DNA sequencing was employed to analyze mutations in p53, PIK3CA, PTEN, BRAF, and CTNNB1 in 12 clear cell (CC), 26 endometrioid (EC), and 51 serous carcinomas (SC).
  • Methylation-specific PCR assessed MLH1 promoter methylation status.
  • Quantitative PCR identified PIK3CA amplification.

Main Results:

  • p53 mutations were frequent in serous carcinomas (49%) and endometrioid carcinomas (42%), but rare in clear cell (8.3%).
  • PTEN mutations were significantly more common in endometrioid (31%) versus clear cell (P = .04) and serous (4%, P = .002) types.
  • CTNNB1 mutations were identified in 23% of endometrioid tumors but none of the clear cell or serous types.
  • PIK3CA mutations occurred in clear cell (25%) and endometrioid (12%) but not serous carcinomas.
  • PIK3CA amplification was observed in 20% of serous carcinomas but not in endometrioid/clear cell types.
  • Endometrioid and clear cell histology correlated with significantly better overall survival (P = .0008).
  • Mutations in p53 or PTEN/PIK3CA represent alternative oncogenic pathways in ovarian cancer.
  • PIK3CA activation occurs via amplification in serous carcinomas and mutation in endometrioid/clear cell types.
  • PTEN and CTNNB1 mutations are associated with low-grade tumors, while PIK3CA mutations are linked to high-grade tumors.

Conclusions:

  • Distinct molecular alterations characterize different epithelial ovarian tumor subtypes.
  • Endometrioid and clear cell ovarian cancers exhibit unique genetic profiles and a more favorable prognosis compared to serous carcinomas.
  • Understanding these subtype-specific molecular pathways is essential for developing personalized treatment strategies in ovarian cancer.

More Related Videos

Heterotypic Three-dimensional In Vitro Modeling of Stromal-Epithelial Interactions During Ovarian Cancer Initiation and Progression12:42

Heterotypic Three-dimensional In Vitro Modeling of Stromal-Epithelial Interactions During Ovarian Cancer Initiation and Progression

Published on: August 28, 2012

Transplantation Into the Mouse Ovarian Fat Pad09:25

Transplantation Into the Mouse Ovarian Fat Pad

Published on: September 7, 2016

Related Concept Videos

Cancers Originate from Somatic Mutations in a Single Cell02:21

Cancers Originate from Somatic Mutations in a Single Cell

Cancer arises from mutations in the critical genes that allow healthy cells to escape cell cycle regulation and acquire the ability to proliferate indefinitely. Though originating from a single mutation event in one of the originator cells, cancer progresses when the mutant cell lines continue to gain more and more mutations, and finally, become malignant. For example, chronic myelogenous leukemia (CML) develops initially as a non-lethal increase in white blood cells, which progressively...
Oogenesis02:07

Oogenesis

In human women, oogenesis produces one mature egg cell or ovum for every precursor cell that enters meiosis. This process differs in two unique ways from the equivalent procedure of spermatogenesis in males. First, meiotic divisions during oogenesis are asymmetric, meaning that a large oocyte (containing most of the cytoplasm) and minor polar body are produced as a result of meiosis I, and again following meiosis II. Since only oocytes will go on to form embryos if fertilized, this unequal...